Przepiorka, D., Ko, C.W., Deisseroth, A., Yancey, C.L., Candau-Chacon, R., Chiu, H.-J., Gehrke, B.J., Gomez-Broughton, C., Kane, R.C., Kirshner, S., Mehrotra, N., Ricks, T.K., Schmiel, D., Song, P., Zhao, P., Zhou, Q., Farrell, A.T. and Pazdur, R. (2015) FDA Approval: Blinatumomab. Clinical Cancer Research, 21, 4035-4039.
https://doi.org/10.1158/1078-0432.CCR-15-0612

has been cited by the following article:

• TITLE: Construction of Multi-Specific Antibody by Genetic Engineering and Its Progress in Tumor Therapy

  AUTHORS: Zhenqi Xu, Can Gao, Mengru Jian, Wei Du

  KEYWORDS: Genetically Engineered, Multi-Specific Antibody, Tumor Therapy

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.11 No.3, March 24, 2023

  ABSTRACT: Targeted treatment of cancer with monoclonal antibodies increases the benefit for patients. In order to improve the anti-tumor activity of monoclonal antibodies, multi-specific antibodies have entered the research field. The emergence of various techniques to produce multi-specific recombinant antibody molecules has led to the selection of target combinations in various forms. To date, only a few multi-specific constructs have entered phase III clinical trials, in contrast to classical monoclonal antibodies. Some of the format options are outlined from a technical point of view. We focus on the achievements and prospects of the underlying technologies for generating biand multispecific antibodies.